Certificate of Analysis and Data Sheet

Source:
SF9 insect cells.

Catalog No.
PKA-319

Description :

Recombinant Human PKC-beta II produced in Sf9 is a glycosylated, polypeptide chain containing amino acids 2-673 and having a molecular mass of 80 KD. PKC-bII is purified by proprietary chromatographic techniques. This protein is the full-length form of the protein with an amino terminal poly His-tag.

Physical Appearance:

Sterile Filtered clear soultion.

Formulation:

Recombinant Human PKC-b II is supplied at a of 0.1mg/ml in 10mM Tris, pH 7.4, 0.1M NaCl, 20% glycerol, 1mM DTT, 0.1mM EDTA, 0.2mM PMSF and 0.03% Brij-35.

Unit Definition:

780 units/mg. One unit of PKCβΙΙ activity transfers 1 nmole of phosphate to a PKC substrate peptide (myelin basic protein 4-14) per minute at 30蚓. Recombinant human active PKCβΙΙ also phosphorylates full length myelin basic protein, histone, HIV Tat-1, GSK-3β and cdk7. Activity requires incubation with lipid activators, and may vary depending on the substrate and reaction conditions.

Storage:

Store at 4蚓 if entire vial will be used within 2-4 weeks. Store, frozen at -20蚓 for longer periods of time.
Please avoid freeze-thaw cycles.

Purity:

Greater than 95% (SDS-PAGE).

Usage:

This material is offered by ProSpec-TechnoGene for research, laboratory or further evaluation purposes.

Latest Publications:

1. Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients?
Diabetes Care 2005 Nov;28(11):2803-5
2. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Ann Pharmacother 2005 Oct;39(10):1693-9
3. [Protein kinase C beta-Inhibitor ruboxistaurin]
Med Monatsschr Pharm 2005 Aug;28(8):292-3
4. Haplotypes in the gene encoding protein kinase c-beta (PRKCB1) on chromosome 16 are associated with autism.
Mol Psychiatry 2005 Oct;10(10):950-60
5. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
Diabetes 2005 Jul;54(7):2188-97
6. Inactivation of 14-3-3 protein exacerbates cardiac hypertrophy and fibrosis through enhanced expression of protein kinase C beta 2 in experimental diabetes.
Biol Pharm Bull 2005 Jun;28(6):957-62